{"title":"【多发性骨髓瘤的治疗】","authors":"J L Harousseau","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The chief advances observed over the last 15 years in the treatment of multiple myeloma arise from intensive procedures and in particular autologous bone marrow transplantation. However, even if autologous bone marrow transplantation increases the rate of total remissions, no plateau is yet observable in the survival curve and transplantation is probably not a curative therapy. Hopes for the future seem to rest on intensive chemotherapy combined with innovative therapeutic approaches such as diphosphonates, thalidomide or immunotherapy.</p>","PeriodicalId":21484,"journal":{"name":"Schweizerische medizinische Wochenschrift","volume":"130 44","pages":"1649-55"},"PeriodicalIF":0.0000,"publicationDate":"2000-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Treatment of multiple myeloma].\",\"authors\":\"J L Harousseau\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The chief advances observed over the last 15 years in the treatment of multiple myeloma arise from intensive procedures and in particular autologous bone marrow transplantation. However, even if autologous bone marrow transplantation increases the rate of total remissions, no plateau is yet observable in the survival curve and transplantation is probably not a curative therapy. Hopes for the future seem to rest on intensive chemotherapy combined with innovative therapeutic approaches such as diphosphonates, thalidomide or immunotherapy.</p>\",\"PeriodicalId\":21484,\"journal\":{\"name\":\"Schweizerische medizinische Wochenschrift\",\"volume\":\"130 44\",\"pages\":\"1649-55\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Schweizerische medizinische Wochenschrift\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Schweizerische medizinische Wochenschrift","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The chief advances observed over the last 15 years in the treatment of multiple myeloma arise from intensive procedures and in particular autologous bone marrow transplantation. However, even if autologous bone marrow transplantation increases the rate of total remissions, no plateau is yet observable in the survival curve and transplantation is probably not a curative therapy. Hopes for the future seem to rest on intensive chemotherapy combined with innovative therapeutic approaches such as diphosphonates, thalidomide or immunotherapy.